Targeted therapies for cancer - From tamoxifen to gefitinib ('Iressa')

Drug Discovery Today: Therapeutic Strategies

Volumn 1, Issue 4, 2004, Pages 411-416

  Hanke, Jeffrey H ^a   Hughes, Les R ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN; ESTROGEN RECEPTOR; FLUOROURACIL; GEFITINIB; PHOSPHATIDYLINOSITOL 3 KINASE; PLATINUM DERIVATIVE; PROTEIN KINASE B; STAT6 PROTEIN; TAMOXIFEN;

ANGIOGENESIS; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CELL DIVISION; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG SENSITIVITY; DRUG TARGETING; ENZYME ACTIVATION; GENE MUTATION; HORMONAL THERAPY; HUMAN; IMMUNOHISTOCHEMISTRY; INHIBITION KINETICS; LUNG NON SMALL CELL CANCER; META ANALYSIS; PATIENT SELECTION; PROGNOSIS; PROTEIN EXPRESSION; RECEPTOR BINDING; REVIEW; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 13344284026     PISSN: 17406773     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddstr.2004.11.002     Document Type: Review

References (52)

1. M.J. Harper and A.L. Walpole A new derivative of triphenylethylene: effect on implantation and mode of action in rats J. Reprod. Fertil. 13 1967 101-119
2. C.K. Osborne Tamoxifen in the treatment of breast cancer N. Engl. J. Med. 339 1998 1609-1618
3. Anonymous Tamoxifen for early breast cancer: An overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group Lancet 351 1998 1451-1467 (see comment)
4. B. Fisher et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study J. Natl. Cancer Inst. 90 1998 1371-1388 (see comment)
5. K. Albain et al. Adjuvant chemohormonal therapy for primary breast cancer should be sequential instead of concurrent: Initial results from intergroup trial 0100 (SWOG-8814) Proceedings of the Amerian Society of Clinical Oncology Annual Meeting 2002, Orlando, FL 2002
6. R. Schiff et al. Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance Clin. Cancer Res. 10 1 Pt 2 2004 331S-336S
7. J. Shou et al. Mechanisms of tamoxifen resistance: Increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer J. Natl. Cancer Inst. 96 2004 926-935 (see comment)
8. Y. Yarden M.X. Sliwkowski Untangling the ErbB signalling network Nat. Rev. Mol. Cell Biol. 2 2001 127-137
9. D.S. Salomon et al. Epidermal growth factor-related peptides and their receptors in human malignancies Crit. Rev. Oncol. Hematol. 19 1995 183-232
10. A.J. Barker et al. Studies leading to the identification of ZD1839 (IRESSA): An orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer Bioorg. Med. Chem. Lett. 11 2001 1911-1914
11. A.E. Wakeling et al. ZD1839 (Iressa): An orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy Cancer Res. 62 2002 5749-5754
12. N.G. Anderson et al. ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression Int. J. Cancer 94 2001 774-782
13. M. Fujimura et al. Selective inhibition of the epidermal growth factor receptor by ZD1839 decreases the growth and invasion of ovarian clear cell adenocarcinoma cells Clin. Cancer Res. 8 2002 2448-2454
14. M. Matsuo et al. ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, shows antimetastatic activity using a hepatocellular carcinoma model Mol. Cancer Ther. 2 2003 557-561
15. J.M. Sewell et al. Targeting the EGF receptor in ovarian cancer with the tyrosine kinase inhibitor ZD 1839 ("Iressa") Br. J. Cancer 86 2002 456-462
16. F.M. Sirotnak et al. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase Clin. Cancer Res. 6 2000 4885-4892
17. F. Ciardiello et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor Clin. Cancer Res. 6 2000 2053-2063
18. C. Bianco et al. Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa) Clin. Cancer Res. 8 2002 3250-3258
19. S.M. Huang et al. Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa) Cancer Res. 62 2002 4300-4306
20. K.J. Williams et al. ZD1839 ('Iressa'), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model Br. J. Cancer 86 2002 1157-1161
21. F.M. Sirotnak et al. Studies with CWR22 xenografts in nude mice suggest that ZD1839 may have a role in the treatment of both androgen-dependent and androgen-independent human prostate cancer Clin. Cancer Res. 8 2002 3870-3876
22. R. Schiff et al. Breast cancer endocrine resistance: How growth factor signaling and estrogen receptor coregulators modulate response Clin. Cancer Res. 9 1 Pt 2 2003 447S-454S
23. G. Tortora et al. Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect Clin. Cancer Res. 9 2003 1566-1572 (see comment)
24. S.L. Moulder et al. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo Cancer Res. 61 2001 8887-8895
25. N. Normanno et al. Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth Ann. Oncol. 13 2002 65-72 (see comment)
26. F. Ciardiello et al. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor Clin. Cancer Res. 7 2001 1459-1465
27. C.J. Barnes et al. Suppression of epidermal growth factor receptor, mitogen-activated protein kinase, and Pak1 pathways and invasiveness of human cutaneous squamous cancer cells by the tyrosine kinase inhibitor ZD1839 (Iressa) Mol. Cancer Ther. 2 2003 345-351
28. A. Hirata et al. ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase Cancer Res. 62 2002 2554-2560
29. M.G. Kris et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial J. Am. Med. Assoc. 290 2003 2149-2158 (see comment)
30. M. Fukuoka et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer J. Clin. Oncol. 21 2003 2237-2246 (see comment)
31. J. Ochs et al. Final survival and safety results for 21,064 non-small cell lung cancer (NSCLC) patients who received compassionate use gefitinib (iressa) in a United States expanded access program Proceedings of the Amerian Society of Clinical Oncology Annual Meeting 2-8 June 2004, New Orleans, LA 2004
32. E. Massarelli et al. A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer Lung Cancer 39 2003 55-61
33. J. Baselga Combined anti-EGF receptor and anti-HER2 receptor therapy in breast cancer: A promising strategy ready for clinical testing Ann. Oncol. 13 2002 8-9 (comment)
34. E.E. Cohen et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck J. Clin. Oncol. 21 2003 1980-1987
35. G. Fischer et al. A phase II study of gefitinib in combination with FOLFOX-4 (IFOX) in patients with metastatic colorectal cancer Proc. Am. Soc. Clin. Oncol. 23 2004 249
36. J.M. Gee et al. The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro Endocrinology 144 2003 5105-5117
37. S. Okubo et al. Additive antitumour effect of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839) and the antioestrogen fulvestrant (Faslodex, ICI 182, 780) in breast cancer cells Br. J. Cancer 90 2004 236-244
38. G. Giaccone et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 1 J. Clin. Oncol. 22 2004 777-784 (see comment)
39. R.S. Herbst et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 2 J. Clin. Oncol. 22 2004 785-794 (see comment)
40. F. Shepherd et al. A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial Proceedings of the Amerian Society of Clinical Oncology 2004 (Vol. Late-Breaking Abstracts Booklet 2004; 23:18, abs 7022)
41. L. Bailey et al. Tumor EGFR membrane staining is not clinically relevant for predicting response in patients receiving gefitinib ('Iressa', ZD1839) monotherapy for pretreated advanced non-small-cell lung cancer: IDEAL 1 and 2 Proceedings of the Amerian Association of Cancer Research 2003 (Vol. 44, 2nd edn), 1362, abs LB-170
42. T.J. Lynch et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N. Engl. J. Med. 350 2004 2129-2139 (see comment)
43. J.G. Paez et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy Science 304 2004 1497-1500 (see comment)
44. V.A. Miller et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer J. Clin. Oncol. 22 2004 1103-1109
45. D.H. Johnson C.L. Arteaga Gefitinib in recurrent non-small-cell lung cancer: An IDEAL trial? J. Clin. Oncol. 21 2003 2227-2229 (comment)
46. M.M. Moasser et al. The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells Cancer Res. 61 2001 7184-7188
47. M. Offterdinger et al. Imaging phosphorylation dynamics of the EGF receptor J. Biol. Chem. 2004 2004 (online, 10.1074/jbc.M405830200)
48. B.S. Hendriks et al. Quantitative analysis of HER2-mediated effects on HER2 and epidermal growth factor receptor endocytosis: Distribution of homo- and heterodimers depends on relative HER2 levels J. Biol. Chem. 278 2003 23343-23351
49. F. Cappuzzo et al. Gefitinib in pretreated non-small-cell lung cancer (NSCLC): Analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC J. Clin. Oncol. 21 2003 2658-2663 (see comment)
50. C. Knuefermann et al. HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells Oncogene 22 2003 3205-3212
51. Sordella, R. et al. (2004) Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-apoptotic Pathways (Vol. 2004), Science Express online
52. P. Stephens et al. Intragenic ERBB2 kinase mutations in tumours Nature 431 2004 525-526